⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84333 | 0.85 | — | — | |
| Bromide SCHEMBL4969616 | 0.81 | — | — | |
| Iodide SCHEMBL4968720 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL2942851 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL6208613 | 0.81 | — | — | |
| Methanesulfonamide SCHEMBL1692407 | 0.79 | CA1 (0.38) | — | |
| SCHEMBL24906918 | 0.76 | — | — | |
| SCHEMBL3900128 | 0.76 | — | — | |
| SCHEMBL21095750 | 0.76 | — | — | |
| SCHEMBL5376449 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | claimed |
| WO-2023114516-A2 | CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-22 | — | — | WO | claimed |
| US-20230151005-A1 | HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-18 | — | — | US | claimed |
| WO-2023049697-A1 | HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-03-30 | — | — | WO | claimed |
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | claimed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | claimed |
| US-6982263-B2 | Nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | claimed |
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | claimed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | claimed |
| EP-1086124-B1 | NOVEL CYCLOSPORINS | CHEM AG C (CH) | 2003-11-19 | — | — | EP | claimed |
| JP-2003529546-A | — | — | 2003-10-07 | — | — | JP | claimed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | claimed |
| US-20030119827-A1 | Novel nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | claimed |
| US-6583265-B1 | Compound for use in the prevention of viral and bacterial infections | C-CHEM AG (CH) | 2003-06-24 | — | — | US | claimed |
| WO-2002100849-A2 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | claimed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | claimed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | claimed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260042777-A1 | PIPERIDYLUREA COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4690339-A2 | ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES THEREOF | Factorial Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025264523-A1 | ELECTROLYTE COMPRISING FOUR OR MORE SALTS AND LITHIUM METAL BATTERIES COMPRISING SAME | FACTORIAL INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| CN-120665074-A | Chiral azabicyclo [2.1.1] hexane derivative intermediate and preparation method thereof | 南方科技大学 | 2025-09-19 | — | — | CN | disclosed |
| CN-120665074-A | Chiral azabicyclo [2.1.1] hexane derivative intermediate and preparation method thereof | 南方科技大学 | 2025-09-19 | — | — | CN | disclosed |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| US-20240360134-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024206364-A2 | ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES THEREOF | FACTORIAL INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4376845-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024104968-A1 | PYRAZOLOPYRROLOPYRIDAZINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| WO-2023247590-A1 | TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247596-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247595-A1 | PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| EP-4289843-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312474-A1 | PHENOL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-05 | — | — | US | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230151005-A1 | HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-05-18 | — | — | US | disclosed |
| EP-4165049-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | Delix Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023049697-A1 | HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-115724799-A | Potassium channel regulator, composition and application | 杭州和正医药有限公司 | 2023-03-03 | — | — | CN | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022258637-A1 | TRISLINKER-CONJUGATED DIMERIC LABELLING PRECURSORS AND RADIOTRACERS DERIVED THEREFROM | Atoms for Cure GmbH (DE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022234867-A1 | SULFONAMIDE HAVING MMP 7-INHIBITING ACTION | 大正製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-3707138-B1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-11166959-B2 | Isofuranone compounds useful as HPK1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
| US-11066425-B1 | Oxo-substituted compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20210147448-A1 | OXO-SUBSTITUTED COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| US-20200390776-A1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3707138-A1 | ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| EP-2883865-B1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO (JP) | 2019-09-25 | — | — | EP | disclosed |
| EP-3133058-B1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10266476-B2 | (Meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2019-04-23 | — | — | US | disclosed |
| US-10065916-B2 | Method for producing (meth)acrylate | TOAGOSEI CO., LTD (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-3002285-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20180237629-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-08-23 | — | — | US | disclosed |
| US-10035752-B2 | Multifunctional (meth)acrylate manufacturing method | TOAGOSEI CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180187026-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180171038-A1 | CURABLE COMPOSITION | TOAGOSEI CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20180118658-A1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180105483-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | TOAGOSEI CO., LTD. (JP) | 2018-04-19 | — | — | US | disclosed |
| EP-3281933-A1 | (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2018-02-14 | — | — | EP | disclosed |
| EP-3269700-A1 | METHOD FOR PRODUCING (METH)ACRYLATE | Toagosei Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20170204044-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO., LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9636330-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-2592081-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-3133058-A1 | MULTIFUNCTIONAL (METH)ACRYLATE MANUFACTURING METHOD | Toagosei Co., Ltd. (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3002285-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20150231118-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-20 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| EP-2883865-A1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-17 | — | — | EP | disclosed |
| US-9006246-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-1661881-B1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2592066-B1 | Aminocarboxylic acid derivative and medical use thereof | ONO PHARMACEUTICAL CO (JP) | 2014-12-03 | — | — | EP | disclosed |
| EP-2371811-B1 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8791159-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20140023636-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8575134-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8506913-B2 | Acidic gas absorbent, acidic gas removal device, and acidic gas removal method | KABUSHIKI KAISHA TOSHIBA (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-2592066-A1 | Aminocarboxylic acid derivative and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592081-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| EP-2554243-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | Kabushiki Kaisha Toshiba (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20120294785-A1 | ACIDIC GAS ABSORBENT, ACIDIC GAS REMOVAL DEVICE, AND ACIDIC GAS REMOVAL METHOD | KABUSHIKI KAISHA TOSHIBA (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| EP-1826197-B1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-8048893-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2011-11-01 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-2371811-A2 | Azetidinecarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-05 | — | — | EP | disclosed |
| US-20110105432-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-7906549-B2 | Aminocarboxylic acid derivative and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7825109-B2 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090275554-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-7524838-B2 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009004383-A2 | AZA-BICYCLOHEXANE COMPOUNDS USEFUL AS ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| US-20090012087-A1 | New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-7279472-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7265132-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1826197-A1 | AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-7056915-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6982272-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-6982263-B2 | Nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-6858623-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6787540-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ASTHMA, OSTEOPOROSIS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-09-07 | — | — | US | disclosed |
| US-6756372-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN'S DISEASE, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, PSORIASIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-6720319-B2 | ((1-(4-CYANO-1-(2-MORPHOLIN-4-YL-ETHYL)-PIPERIDIN-4 -YLCARBAMOYL)- 2-CYCLOHEXYL-ETHYLAMINO) -MORPHOLIN-4-YL-METHYLENE)- CARBAMIC ACID ISOBUTYL ESTER; CATHEPSINS S, K, F, L AND B; AUTOIMMUNE DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| EP-1399431-A2 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030232826-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACIUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030216383-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1086124-B1 | NOVEL CYCLOSPORINS | CHEM AG C (CH) | 2003-11-19 | — | — | EP | disclosed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-1322613-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119827-A1 | Novel nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| US-6583265-B1 | Compound for use in the prevention of viral and bacterial infections | C-CHEM AG (CH) | 2003-06-24 | — | — | US | disclosed |
| US-6525052-B2 | Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| WO-2002100849-A2 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020137932-A1 | Novel compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-09-26 | — | — | US | disclosed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
| WO-2002020485-A1 | SPIROHETEROCYCLIC NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1086124-A1 | NOVEL CYCLOSPORINS | C-Chem AG (CH) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-1999065933-A1 | NOVEL CYCLOSPORINS | C-CHEM AG (CH) | 1999-12-23 | — | — | WO | disclosed |
| US-4292190-A | ANTIFREEZES FOR COOLING SYSTEMS OF INTERNAL COMBUSTION ENGINES | BASF WYANDOTTE CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
| US-4292190-A | ANTIFREEZES FOR COOLING SYSTEMS OF INTERNAL COMBUSTION ENGINES | BASF WYANDOTTE CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |